ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company’s stock dropped following this news.
businessWire Story
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company’s stock dropped following this news.
